- Home
- QSI vs CRGX Comparison
QSI vs CRGX Comparison
Compare QSI & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- CRGX
- Stock Information
- Founded
- QSI 2013
- CRGX 2021
- Country
- QSI United States
- CRGX United States
- Employees
- QSI N/A
- CRGX N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- CRGX
- Sector
- QSI Health Care
- CRGX
- Exchange
- QSI Nasdaq
- CRGX Nasdaq
- Market Cap
- QSI 633.2M
- CRGX 621.4M
- IPO Year
- QSI N/A
- CRGX 2023
- Fundamental
- Price
- QSI $2.35
- CRGX $12.04
- Analyst Decision
- QSI Buy
- CRGX Strong Buy
- Analyst Count
- QSI 2
- CRGX 6
- Target Price
- QSI $3.25
- CRGX $31.80
- AVG Volume (30 Days)
- QSI 59.3M
- CRGX 301.4K
- Earning Date
- QSI 02-27-2025
- CRGX 11-12-2024
- Dividend Yield
- QSI N/A
- CRGX N/A
- EPS Growth
- QSI N/A
- CRGX N/A
- EPS
- QSI N/A
- CRGX N/A
- Revenue
- QSI $2,266,000.00
- CRGX N/A
- Revenue This Year
- QSI $193.90
- CRGX N/A
- Revenue Next Year
- QSI $173.18
- CRGX N/A
- P/E Ratio
- QSI N/A
- CRGX N/A
- Revenue Growth
- QSI 232.26
- CRGX N/A
- 52 Week Low
- QSI $0.61
- CRGX $10.91
- 52 Week High
- QSI $5.77
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- QSI 50.30
- CRGX 37.21
- Support Level
- QSI $1.85
- CRGX $10.91
- Resistance Level
- QSI $5.77
- CRGX $15.75
- Average True Range (ATR)
- QSI 0.87
- CRGX 1.19
- MACD
- QSI -0.15
- CRGX -0.17
- Stochastic Oscillator
- QSI 24.17
- CRGX 22.97
About QSI Quantum-Si Incorporated
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.